Pembrolizumab-Induced Ocular Myasthenic Crisis

Pembrolizumab, one of many novel immune checkpoint inhibitors (ICPi), is a monoclonal antibody that enhances immunity against cancer cells. Extensive escalation in immune activity predisposes to unsought immune-related adverse events. Due to progressive mesothelioma, a 67-year-old man was referred t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzo, Christian J, Fitzpatrick, Haley, Campdesuner, Victoria, George, Justin, Lattanzio, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366038/
https://www.ncbi.nlm.nih.gov/pubmed/32685327
http://dx.doi.org/10.7759/cureus.9192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366038/
https://www.ncbi.nlm.nih.gov/pubmed/32685327
http://dx.doi.org/10.7759/cureus.9192

Ejemplares similares